VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Bristol-Myers Squibb Company vs Thomson Reuters Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisThomson Reuters Corporation
TRI · Toronto Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Thomson Reuters Corporation's moat claims, evidence, and risks.
View TRI analysisComparison highlights
- Moat score gap: Thomson Reuters Corporation leads (84 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)); Thomson Reuters Corporation has 5 segments (40.1% in Legal Professionals).
- Primary market structure: Oligopoly vs Duopoly. Pricing power: Moderate vs Strong.
- Moat breadth: Bristol-Myers Squibb Company has 4 moat types across 3 domains; Thomson Reuters Corporation has 4 across 3.
Primary market context
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Thomson Reuters Corporation
Legal Professionals
Legal research and legal workflow software
Global
Law firms, corporate legal departments, and governments
Subscription software + proprietary legal content
40.1%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Bristol-Myers Squibb Company strengths
Thomson Reuters Corporation strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Thomson Reuters Corporation segments
Full profile >Legal Professionals
Duopoly
Corporates
Oligopoly
Tax & Accounting Professionals
Oligopoly
Reuters News
Oligopoly
Global Print
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.